Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Several technologies for hemoglobinopathies are being transferred to commercial partners
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
The new site enables end-to-end production of viral vector gene therapies
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Subscribe To Our Newsletter & Stay Updated
